期刊
FRONTIERS IN IMMUNOLOGY
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.974016
关键词
influenza vaccine; adjuvant; ADCC; T cell; antibody class switching; HA stalk; neuraminidase
类别
资金
- CRIPT (Center for Research on Influenza Pathogenesis and Transmission)
- NIH NIAID [75N93021C00014, 1R21AI146529, R21AI151229]
- NIAID [75N93019C00051, P01AI097092]
- JBP foundation
- OPP [2020-215611 (5384)]
- NIH/NIAID CEIRS [HHSN272201400008C]
- European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program [817938]
- Swiss National Science Foundation [P400PB_199292]
- Swiss National Science Foundation (SNF) [P400PB_199292] Funding Source: Swiss National Science Foundation (SNF)
- European Research Council (ERC) [817938] Funding Source: European Research Council (ERC)
The effectiveness of influenza vaccine can be improved by using adjuvants that enhance the host-vaccine response. This study investigated the use of two adjuvants, RIG-I agonist (SDI-nanogel) and TLR7/8 agonist (Imidazoquinoline (IMDQ)-PEG-Chol), in combination with a licensed quadrivalent inactivated influenza vaccine (QIV). The results showed that co-administration of QIV with these adjuvants enhanced the immune response, resulting in increased antibody titers and T cell responses. The combination of the two adjuvants had a stronger effect compared to using a single adjuvant. The findings highlight the importance of adjuvants that target multiple receptors in shaping the host immune response.
Influenza vaccine effectiveness could be improved by combination with an adjuvant with the potential to enhance the host-vaccine response both quantitatively and qualitatively. The goal of this study was to explore a RIG-I agonist (SDI-nanogel) and a TLR7/8 agonist (Imidazoquinoline (IMDQ)-PEG-Chol) as adjuvants, when co-administered with a licensed quadrivalent inactivated influenza vaccine (QIV), and to determine the role of these adjuvants in directing helper T (Th) cell responses for their role in the immunoglobulin (Ig) class switching. Administration of QIV with the two adjuvants, individually or combined, resulted in enhanced HA-specific serum ELISA IgG titers, serum hemagglutination inhibition (HAI) titers and splenic T cell responses as examined by IFN-gamma and IL-4 enzyme-linked immunosorbent spot (ELISPOT) assays, 4-weeks post-prime and post-boost vaccination in BALB/c mice. While QIV+SDI-nanogel largely induced antigen-specific IgG1 responses, QIV+IMDQ-PEG-Chol predominantly induced IgG2a antibody isotypes post-prime vaccination, suggesting efficient induction of Th2 (IL-4) and Th1 (IFN-gamma) responses, respectively. Combination of the two adjuvants not only skewed the response completely towards IgG2a, but also resulted in induction of HAI titers that outperformed groups that received single adjuvant. Moreover, enhanced IgG2a titers correlate with antibody-mediated cellular cytotoxicity (ADCC) that targets both the highly conserved H1 hemagglutination (HA) stalk domain and N1 neuraminidase (NA). A booster vaccination with QIV+IMDQ-PEG-Chol resulted in a more balanced IgG1/IgG2a response in animals primed with QIV+IMDQ-PEG-Chol but increased only IgG2a titers in animals that received the combination adjuvant during prime vaccination, suggesting that class switching events in germinal centers during the prime vaccination contribute to the outcome of booster vaccination. Importantly, IMDQ-PEG-Chol, alone or in combination, always outperformed the oil-in-water control adjuvant Addavax. Vaccine-induced antibody and T cell responses correlated with protection against lethal influenza virus infection. This study details the benefit of adjuvants that target multiple innate immune receptors to shape the host vaccine response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据